Omnia Family Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Omnia Family Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22	Closed	-$2K	–	573
2018 Q1	$2K	Hold	22	–	–	﹤0.01%	415
2017 Q4	$2K	Hold	22	–	–	﹤0.01%	417
2017 Q3	$2K	Sell	22 -52	-70%	-$4.59K	﹤0.01%	437
2017 Q2	$7K	Hold	74	–	–	﹤0.01%	333
2017 Q1	$6K	Buy	74 +22	+42%	+$1.96K	﹤0.01%	344
2016 Q4	$4K	Buy	+52	New	+$4.47K	﹤0.01%	419

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Omnia Family Wealth's BMRN Position: Q2 2018 in Review

Omnia Family Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 22 shares — an estimated $2K sold.

Omnia Family Wealth first reported a position in BMRN in Q4 2016 and held it in 6 quarters. The position peaked at $7K in Q2 2017. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Omnia Family Wealth reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Omnia Family Wealth sold 22 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2K.
Omnia Family Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 6 quarters.
Omnia Family Wealth's BioMarin Pharmaceuticals position peaked at $7K in Q2 2017.
449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Omnia Family Wealth's 13F filing for Q2 2018, filed 10 Aug 2018.